Clinical Introduction of Lysophosphatidic Acid (LPA) and Autotaxin Assays

Lysophospholipid Receptors: Signaling and Biochemistry

Volumn , Issue , 2013, Pages 709-735

  Yatomi, Yutaka ^a,b   Igarashi, Koji ^c   Nakamura, Kazuhiro ^a   Ohkawa, Ryunosuke ^a   Masuda, Akiko ^a   Suzuki, Akiko ^b   Kishimoto, Tatsuya ^d   Ikeda, Hitoshi ^a,b   Aoki, Junken ^e  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOSOH CORPORATION   (Japan)

^d Alfresa Pharma Corporation   (Japan)

^e TOHOKU UNIVERSITY   (Japan)

Author keywords

ATX EIA, ATX in LPA regulation; CSF ATX in lab, and ATX fluid changes; LPA, physio patho responses with GPCR; LPA autotaxin assay, clinicals; Plasma LPA measurement

Indexed keywords

EID: 84886450399     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118531426.ch33     Document Type: Chapter

References (100)

1. Mills GB, Moolenaar WH. 2003. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3:582-591.
2. Moolenaar WH, van Meeteren LA, Giepmans BN. 2004. The ins and outs of lysophosphatidic acid signaling. Bioessays 26:870-881.
3. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, et al. 2009. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15:539-550.
4. Nakanaga K, Hama K, Aoki J. 2010. Autotaxin-an LPA producing enzyme with diverse functions. J Biochem 148:13-24.
5. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, et al. 2003. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A 100:131-136.
6. Aoki J, Inoue A, Okudaira S. 2008. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 1781:513-518.
7. Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, et al. 2002. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 277:48737-48744.
8. Yatomi Y, Ohmori T, Rile G, Kazama F, Okamoto H, et al. 2000. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 96:3431-3438.
9. Nishimasu H, Okudaira S, Hama K, Mihara E, Dohmae N, et al. 2011. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol 18:205-212.
10. Okudaira S, Yukiura H, Aoki J. 2010. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 92:698-706.
11. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, et al. 2002. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 277: 39436-39442.
12. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, et al. 2002. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158:227-233.
13. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, et al. 1992. Identification, purification, and partial sequence analysis of autotaxin, a novel motilitystimulating protein. J Biol Chem 267:2524-2529.
14. Dennis J, White MA, Forrest AD, Yuelling LM, Nogaroli L, et al. 2008. Phosphodiesterase-Ialpha/autotaxin's MORFO domain regulates oligodendroglial process network formation and focal adhesion organization. Mol Cell Neurosci 37:412-424.
15. Yuelling LM, Fuss B. 2008. Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties. Biochim Biophys Acta 1781:525-530.
16. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, et al. 2006. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 281:25822-25830.
17. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, et al. 2006. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26:5015-5022.
18. Nakamura K, Takeuchi T, Ohkawa R, Okubo S, Yokota H, et al. 2007. Serum lysophospholipase D/autotaxin may be a new nutritional assessment marker: study on prostate cancer patients. Ann Clin Biochem 44:549-456.
19. Kishimoto T, Matsuoka T, Imamura S, Mizuno K. 2003. A novel colorimetric assay for the determination of lysophosphatidic acid in plasma using an enzymatic cycling method. Clin Chim Acta 333:59-67.
20. Nakamura K, Kishimoto T, Ohkawa R, Okubo S, Tozuka M, et al. 2007. Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: proposal of a plasma sample preparation method for laboratory testing of these lipids. Anal Biochem 367:20-27.
21. Nakamura K, Ohkawa R, Okubo S, Tozuka M, Okada M, et al. 2007. Measurement of lysophospholipase D/autotaxin activity in human serum samples. Clin Biochem 40:274-277.
22. Sasagawa T, Okita M, Murakami J, Kato T, Watanabe A. 1999. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids 34:17-21.
23. Chen X, Yang XY, Wang ND, Ding C, Yang YJ, et al. 2003. Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction. Scand J Clin Lab Invest 63:497-503.
24. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, et al. 1998. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280:719-723.
25. Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC, Jr., et al. 2004. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13:1185-1191.
26. Baker DL, Morrison P, Miller B, Riely CA, Tolley B, et al. 2002. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 287:3081-3082.
27. Smyth SS, Cheng HY, Miriyala S, Panchatcharam M, Morris AJ. 2008. Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim Biophys Acta 1781:563-570.
28. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K. 2000. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett 478:159-165.
29. Yoshida K, Nishida W, Hayashi K, Ohkawa Y, Ogawa A, et al. 2003. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 108:1746-1752.
30. Murph M, Tanaka T, Pang J, Felix E, Liu S, et al. 2007. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol 433:1-25.
31. Scherer M, Schmitz G, Liebisch G. 2009. High-throughput analysis of sphingosine 1-phosphate, sphinganine 1-phosphate, and lysophosphatidic acid in plasma samples by liquid chromatography-tandem mass spectrometry. Clin Chem 55: 1218-1222.
32. Ogiso H, Suzuki T, Taguchi R. 2008. Development of a reverse-phase liquid chromatography electrospray ionization mass spectrometry method for lipidomics, improving detection of phosphatidic acid and phosphatidylserine. Anal Biochem 375:124-131.
33. Albers HM, Dong A, van Meeteren LA, Egan DA, Sunkara M, et al. 2010. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A 107:7257-6722.
34. Gierse J, Thorarensen A, Beltey K, Bradshaw-Pierce E, Cortes-Burgos L, et al. 2010. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther 334:310-317.
35. Macey M, Azam U, McCarthy D, Webb L, Chapman ES, et al. 2002. Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. Clin Chem 48:891-899.
36. Hosogaya S, Yatomi Y, Nakamura K, Ohkawa R, Okubo S, et al. 2008. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann Clin Biochem 45:364-368.
37. Nakamura K, Igarashi K, Ide K, Ohkawa R, Okubo S, et al. 2008. Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clin Chim Acta 388:51-58.
38. Ferry G, Tellier E, Try A, Gres S, Naime I, et al. 2003. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 278:18162-18169.
39. Gesta S, Simon MF, Rey A, Sibrac D, Girard A, et al. 2002. Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis. J Lipid Res 43:904-910.
40. Ikeda H, Yatomi Y, Yanase M, Satoh H, Nishihara A, et al. 1998. Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochem Biophys Res Commun 248:436-440.
41. Yanase M, Ikeda H, Matsui A, Maekawa H, Noiri E, et al. 2000. Lysophosphatidic acid enhances collagen gel contraction by hepatic stellate cells: association with rho-kinase. Biochem Biophys Res Commun 277:72-78.
42. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, et al. 2007. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 41:616-623.
43. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, et al. 2007. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci 81:1009-1015.
44. Nakagawa H, Ikeda H, Nakamura K, Ohkawa R, Masuzaki R, et al. 2011. Autotaxin as a novel serum marker of liver fibrosis. Clin Chim Acta 412:1201-1216.
45. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, et al. 2011. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 53:726-736.
46. Jansen S, Andries M, Vekemans K, Vanbilloen H, Verbruggen A, Bollen M. 2009. Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett 284:216-221.
47. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, et al. 2008. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 14:45-54.
48. Pradere JP, Gonzalez J, Klein J, Valet P, Gres S, et al. 2008. Lysophosphatidic acid and renal fibrosis. Biochim Biophys Acta 1781:582-587.
49. Liu S, Murph M, Panupinthu N, Mills GB. 2009. ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 8:3695-3701.
50. Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, et al. 2002. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 107:259-283.
51. Karam AK, Karlan BY. 2010. Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol 7:335-339.
52. Qi C, Park JH, Gibbs TC, Shirley DW, Bradshaw CD, et al. 1998. Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells. J Cell Physiol 174:261-272.
53. Daaka Y. 2002. Mitogenic action of LPA in prostate. Biochim Biophys Acta 1582: 265-269.
54. Nakai Y, Ikeda H, Nakamura K, Kume Y, Fujishiro M, et al. 2011. Specific increase in serum autotaxin activity in patients with pancreatic cancer. Clin Biochem 44: 576-581.
55. Baumforth KR, Flavell JR, Reynolds GM, Davies G, Pettit TR, et al. 2005. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 106:2138-2146.
56. Masuda A, Nakamura K, Izutsu K, Igarashi K, Ohkawa R, et al. 2008. Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol 143:60-70.
57. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. 2010. Prognostic factors in follicular lymphoma. J Clin Oncol 28:2902-2913.
58. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD. 2008. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol 9:415-423.
59. Ye X, Chun J. 2010. Lysophosphatidic acid (LPA) signaling in vertebrate reproduction. Trends Endocrinol Metab 21:17-24.
60. Hama K, Aoki J, Inoue A, Endo T, Amano T, et al. 2007. Embryo spacing and implantation timing are differentially regulated by LPA3-mediated lysophosphatidic acid signaling in mice. Biol Reprod 77:954-959.
61. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, et al. 2005. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435: 104-108.
62. Tokumura A, Kanaya Y, Miyake M, Yamano S, Irahara M, Fukuzawa K. 2002. Increased production of bioactive lysophosphatidic acid by serum lysophospholipase D in human pregnancy. Biol Reprod 67:1386-1392.
63. Iwasawa Y, Fujii T, Nagamatsu T, Kawana K, Okudaira S, et al. 2009. Expression of autotaxin, an ectoenzyme that produces lysophosphatidic acid, in human placenta. Am J Reprod Immunol 62:90-95.
64. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, et al. 2010. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50:157-186.
65. Lin ME, Herr DR, Chun J. 2010. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 91:130-138.
66. Ma L, Uchida H, Nagai J, Inoue M, Aoki J, Ueda H. 2010. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain. J Pharmacol Exp Ther 333:540-546.
67. Tanaka M, Kishi Y, Takanezawa Y, Kakehi Y, Aoki J, Arai H. 2004. Prostatic acid phosphatase degrades lysophosphatidic acid in seminal plasma. FEBS Lett 571: 197-204.
68. Nakamura K, Ohkawa R, Okubo S, Yokota H, Ikeda H, et al. 2009. Autotaxin enzyme immunoassay in human cerebrospinal fluid samples. Clin Chim Acta 405: 160-162.
69. Caner H, Kwan AL, Bavbek M, Kilinc K, Durieux M, et al. 2000. Systemic administration of mexiletine for attenuation of cerebral vasospasm following experimental subarachnoid haemorrhage. Acta Neurochir (Wien) 142:455-461.
70. Yakubu MA, Leffler CW. 1999. Regulation of ET-1 biosynthesis in cerebral microvascular endothelial cells by vasoactive agents and PKC. Am J Physiol 276: C300-C305.
71. Kamanna VS, Bassa BV, Ganji SH, Roh DD. 2005. Bioactive lysophospholipids and mesangial cell intracellular signaling pathways: role in the pathobiology of kidney disease. Histol Histopathol 20:603-613.
72. Ohkawa R, Hisano N, Nakamura K, Okubo S, Yokota H, Yatomi Y. 2006. Lysophospholipase D activity exists in the urine to catalyse the formation of lysophosphatidic acid. Nephrol Dial Transplant 21:3612-3613.
73. Nakamura K, Nangaku M, Ohkawa R, Okubo S, Yokota H, et al. 2008. Analysis of serum and urinary lysophospholipase D/autotaxin in nephrotic syndrome. Clin Chem Lab Med 46:150-151.
74. Lee HY, Murata J, Clair T, Polymeropoulos MH, Torres R, et al. 1996. Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem Biophys Res Commun 218:714-719.
75. Stracke ML, Clair T, Liotta LA. 1997. Autotaxin, tumor motility-stimulating exophosphodiesterase. Adv Enzyme Regul 37:135-144.
76. Jansen S, Stefan C, Creemers JW, Waelkens E, Van Eynde A, et al. 2005. Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D. J Cell Sci 118:3081-3089.
77. Koike S, Keino-Masu K, Ohto T, Masu M. 2006. The N-terminal hydrophobic sequence of autotaxin (ENPP2) functions as a signal peptide. Genes Cells 11:133-142.
78. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, et al. 2004. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 279:17634-17639.
79. Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, et al. 2001. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 61: 6938-6944.
80. David M, Wannecq E, Descotes F, Jansen S, Deux B, et al. 2010. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. PLoS ONE 5:e9741.
81. Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, et al. 2004. Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer 109: 833-838.
82. Stassar MJ, Devitt G, Brosius M, Rinnab L, Prang J, et al. 2001. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer 85:1372-1382.
83. Debies MT, Welch DR. 2001. Genetic basis of human breast cancer metastasis. J Mammary Gland Biol Neoplasia 6:441-451.
84. Zhang G, Zhao Z, Xu S, Ni L, Wang X. 1999. Expression of autotaxin mRNA in human hepatocellular carcinoma. Chin Med J (Engl) 112:330-332.
85. Yang Y, Mou L, Liu N, Tsao MS. 1999. Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 21:216-222.
86. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, et al. 2006. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 281:17492-17500.
87. Rosskopf D, Daelman W, Busch S, Schurks M, Hartung K, et al. 1998. Growth factor-like action of lysophosphatidic acid on human B lymphoblasts. Am J Physiol 274:C1573-C1582.
88. Hu X, Haney N, Kropp D, Kabore AF, Johnston JB, Gibson SB. 2005. Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB. J Biol Chem 280:9498-9508.
89. Satoh Y, Ohkawa R, Nakamura K, Higashi K, Kaneko M, et al. 2007. Lysophosphatidic acid protection against apoptosis in the human pre-B-cell line Nalm-6. Eur J Haematol 78:510-517.
90. Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S. 2005. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol 169:801-811.
91. Spiegel S, Milstien S. 2005. Critical role of acylglycerol kinase in epidermal growth factor-induced mitogenesis of prostate cancer cells. Biochem Soc Trans 33: 1362-1365.
92. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, et al. 2005. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128:343-350.
93. Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. 2007. Ultrasoundbased transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 5:1214-1220.
94. Wallace VC, Cottrell DF, Brophy PJ, Fleetwood-Walker SM. 2003. Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids. J Neurosci 23:3221-3233.
95. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H. 2004. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 10:712-718.
96. Inoue M, Xie W, Matsushita Y, Chun J, Aoki J, Ueda H. 2008. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience 152:296-298.
97. Inoue M, Ma L, Aoki J, Chun J, Ueda H. 2008. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain 4:6.
98. Hammack BN, Fung KY, Hunsucker SW, Duncan MW, Burgoon MP, et al. 2004. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 10: 245-260.
99. Hoeglund AB, Bostic HE, Howard AL, Wanjala IW, Best MD, et al. 2010. Optimization of a pipemidic acid autotaxin inhibitor. J Med Chem 53:1056-1066.
100. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, et al. 2009. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 69:5441-5449.